Piscataqua Savings Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Piscataqua Savings Bank’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.2K	Hold	12,499	–	–	0.01%	307
2026 Q1	$19.6K	Hold	12,499	–	–	0.01%	281
2025 Q4	$20.7K	Hold	12,499	–	–	0.01%	269
2025 Q3	$21.1K	Hold	12,499	–	–	0.02%	232
2025 Q2	$11.2K	Hold	12,499	–	–	0.01%	277
2025 Q1	$5.62K	Hold	12,499	–	–	0.01%	297
2024 Q4	$6.25K	Hold	12,499	–	–	0.01%	295
2024 Q3	$11.2K	Hold	12,499	–	–	0.01%	265
2024 Q2	$12.4K	Hold	12,499	–	–	0.01%	252
2024 Q1	$18.5K	Hold	12,499	–	–	0.02%	238
2023 Q4	$13.5K	Hold	12,499	–	–	0.01%	246
2023 Q3	$14.6K	Hold	12,499	–	–	0.01%	244
2023 Q2	$17.5K	Hold	12,499	–	–	0.01%	242
2023 Q1	$18.7K	Hold	12,499	–	–	0.02%	232
2022 Q4	$14.5K	Hold	12,499	–	–	0.01%	246
2022 Q3	$14K	Hold	12,499	–	–	0.01%	234
2022 Q2	$20K	Hold	12,499	–	–	0.02%	215
2022 Q1	$19K	Hold	12,499	–	–	0.01%	230
2021 Q4	$31K	Hold	12,499	–	–	0.02%	191
2021 Q3	$31K	Hold	12,499	–	–	0.03%	187
2021 Q2	$35K	Hold	12,499	–	–	0.03%	182
2021 Q1	$29K	Buy	+12,499	New	+$30K	0.03%	188

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Piscataqua Savings Bank's LCTX Position: Q2 2026 in Review

Piscataqua Savings Bank held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 12,499 shares worth $16.2K. The position accounts for 0.01% of the portfolio, ranked #307.

Piscataqua Savings Bank first reported a position in LCTX in Q1 2021 and has held it in 22 quarters since. The position peaked at $35K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Piscataqua Savings Bank held 12,499 shares of Lineage Cell Therapeutics worth $16.2K as of Q2 2026.
Piscataqua Savings Bank left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up 0.01% of Piscataqua Savings Bank's portfolio in Q2 2026, its #307 holding.
Piscataqua Savings Bank first reported a position in Lineage Cell Therapeutics in Q1 2021 and has held it in 22 quarters since.
Piscataqua Savings Bank's Lineage Cell Therapeutics position peaked at $35K in Q2 2021.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Piscataqua Savings Bank's 13F filing for Q2 2026, filed 9 Jul 2026.